My Path Nelnaom – pro
Myriad myPath Melanoma is a clinically validated test to be used as an adjunct to histopathology when the distinction between a benign nevus and a malignant melanoma cannot be made confidently by histopathology alone. The test measures the expression of 23 genes and accurately distinguishes melanoma from benign nevi. It is covered by Medicare.
Clarke L, et al. Clinical validity of a gene expression signature in diagnostically uncertain neoplasms Personalized Medicine. 2020
Clarke LE, Leachman SA. Reply to Reimann et al. Mod Pathol. 2019 May;32(5):725-727. doi: 10.1038/s41379-018-0197-1. Epub 2019 Jan 21. PMID: 30666051; PMCID: PMC6760647.
Real world validation of an adjunctive gene expression–profiling assay for melanoma diagnosis and correlation with clinical outcomes at an academic center.Human Pathology Volume 139, September 2023, Pages 73-79